Literature DB >> 9231965

Freeze-dried allograft for posterior spinal fusion in patients with neuromuscular spinal deformities.

M Yazici1, M A Asher.   

Abstract

STUDY
DESIGN: The effectiveness and safety of freeze-dried allograft for posterior spinal fusion in patients with neuromuscular disorders were evaluated retrospectively. SUMMARY OF BACKGROUND DATA: Because the harvest of an adequate quantity of autogenous bone graft from patients with neuromuscular deformity who have instrumentation and fusion to the pelvis is difficult at best, an alternative graft source usually is needed. Allograft bone, most commonly processed fresh-frozen or freeze-dried, has been used frequently for posterior spinal fusion in patients with neuromuscular deformity. However, a relatively high risk of infection and pseudarthrosis has been reported for this procedure.
METHODS: Forty patients with neuromuscular deformity with an average age at the time of surgery of 14 years and 2 months (range, 5 years, 4 months to 23 years, 8 months) met the inclusion criteria. All of these patients underwent more than 2 years of follow-up evaluation. They were evaluated for rates of infection, pseudarthrosis, and transmissible disease.
RESULTS: Thirty-eight patients had solid fusion at the most recent follow-up visit. Definite pseudarthrosis was detected in one patient (2.5% of the study group), which was treated successfully. Another patient's (2.5%) spinal curve progression of more that 10 degrees and rod breakage led the authors to diagnoses a probable pseudarthrosis. She had a stable spine that did not require revision at 68 months after surgery. For the 32 patients who underwent posterior surgery only, the pseudarthrosis rate was 3.1%. There were no acute deep wound infections. Superficial infection occurred in two patients (5%) and delayed deep sterile drainage in one patient (2.5%). All cases of infection resolved with appropriate management. Delayed deep wound infection developed in one patient (2.5%) as a result of staphylococcus coagulase negative at 34 months after surgery. Successful treatment has consisted of implant removal, debridement, and appropriate antibiotics. Transmissible disease attributable to allograft has not been detected to date.
CONCLUSION: Freeze-dried allograft fusion is a reliable and effective method for posterior spinal fusion in the patients with neuromuscular deformity.

Entities:  

Mesh:

Year:  1997        PMID: 9231965     DOI: 10.1097/00007632-199707010-00008

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  6 in total

Review 1.  [Bone substitutes in scoliosis surgery].

Authors:  T Lerner; H Griefingholt; U Liljenqvist
Journal:  Orthopade       Date:  2009-02       Impact factor: 1.087

2.  The clinical use of allografts, demineralized bone matrices, synthetic bone graft substitutes and osteoinductive growth factors: a survey study.

Authors:  Mathias P G Bostrom; Daniel A Seigerman
Journal:  HSS J       Date:  2005-09

3.  Deep wound infection following pediatric scoliosis surgery: incidence and analysis of risk factors.

Authors:  Sami Aleissa; David Parsons; John Grant; James Harder; Jason Howard
Journal:  Can J Surg       Date:  2011-08       Impact factor: 2.089

4.  Bone substitutes and expanders in Spine Surgery: A review of their fusion efficacies.

Authors:  Abhijeet Kadam; Paul W Millhouse; Christopher K Kepler; Kris E Radcliff; Michael G Fehlings; Michael E Janssen; Rick C Sasso; James J Benedict; Alexander R Vaccaro
Journal:  Int J Spine Surg       Date:  2016-09-22

5.  Silicate-substituted calcium phosphate as a bone graft substitute in surgery for adolescent idiopathic scoliosis.

Authors:  Thomas Lerner; Ulf Liljenqvist
Journal:  Eur Spine J       Date:  2012-09-05       Impact factor: 3.134

6.  Bone grafting options for lumbar spine surgery: a review examining clinical efficacy and complications.

Authors:  Kenneth Vaz; Kushagra Verma; Themistocles Protopsaltis; Frank Schwab; Baron Lonner; Thomas Errico
Journal:  SAS J       Date:  2010-09-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.